DIVISLAB

Divi’s Labs is a global powerhouse in Active Pharmaceutical Ingredients (APIs), supplying key components to pharmacies worldwide. They are the world's leading producer for about ten specific APIs, which speaks volumes about their expertise and quality control – vital in an industry with strict regulatory checks. Their innovation and strong compliance mean fewer issues with bodies like the US FDA, adding to their reliability. Divi’s boasts a diverse global client base, ensuring stable revenue and improving earnings, underscoring strong financial health. I see Divi’s as a high-conviction long-term pharma play. My analysis suggests this stock could potentially triple your investment by the end of 2030, hitting a target of ₹18,000 if held for four years or more. For those with a long-term vision, gradually investing in Divi’s could be a smart move for wealth creation.